Biogen Inc. (0R1B.L)
USD 122.29
(-2.27%)
USD 122.29
(-2.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.04 Billion USD | 7.88% |
| 2022 | 11.16 Billion USD | -13.56% |
| 2021 | 12.91 Billion USD | -7.29% |
| 2020 | 13.93 Billion USD | 0.27% |
| 2019 | 13.89 Billion USD | 13.36% |
| 2018 | 12.25 Billion USD | 10.88% |
| 2017 | 11.05 Billion USD | 2.85% |
| 2016 | 10.74 Billion USD | 6.1% |
| 2015 | 10.12 Billion USD | 189.22% |
| 2014 | 3.5 Billion USD | 8.02% |
| 2013 | 3.24 Billion USD | 2.41% |
| 2012 | 3.16 Billion USD | 20.73% |
| 2011 | 2.62 Billion USD | -0.77% |
| 2010 | 2.64 Billion USD | 15.42% |
| 2009 | 2.28 Billion USD | -14.33% |
| 2008 | 2.67 Billion USD | -13.62% |
| 2007 | 3.09 Billion USD | 120.56% |
| 2006 | 1.4 Billion USD | -3.97% |
| 2005 | 1.46 Billion USD | -37.54% |
| 2004 | 2.33 Billion USD | -4.54% |
| 2003 | 2.45 Billion USD | 495.44% |
| 2002 | 411.56 Million USD | 10.57% |
| 2001 | 372.21 Million USD | 14.37% |
| 2000 | 325.45 Million USD | 9.05% |
| 1999 | 298.44 Million USD | 44.8% |
| 1998 | 206.1 Million USD | -25.74% |
| 1997 | 277.53 Million USD | 84.77% |
| 1996 | 150.2 Million USD | 74.21% |
| 1995 | 86.22 Million USD | 79.9% |
| 1994 | 47.92 Million USD | 50.72% |
| 1993 | 31.8 Million USD | 21.37% |
| 1992 | 26.2 Million USD | 85.82% |
| 1991 | 14.1 Million USD | 10.16% |
| 1990 | 12.8 Million USD | 113.33% |
| 1989 | 6 Million USD | -53.49% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.35 Billion USD | -5.73% |
| 2024 Q2 | 10.91 Billion USD | -3.87% |
| 2024 Q3 | 11.21 Billion USD | 9.52% |
| 2023 Q3 | 13.71 Billion USD | 28.21% |
| 2023 Q2 | 10.69 Billion USD | -1.06% |
| 2023 FY | 12.04 Billion USD | 7.88% |
| 2023 Q1 | 10.81 Billion USD | -3.17% |
| 2023 Q4 | 12.04 Billion USD | -12.16% |
| 2022 Q1 | 12.39 Billion USD | -4.06% |
| 2022 FY | 11.16 Billion USD | -13.56% |
| 2022 Q4 | 11.16 Billion USD | -7.63% |
| 2022 Q3 | 12.08 Billion USD | -8.55% |
| 2022 Q2 | 13.21 Billion USD | 6.65% |
| 2021 FY | 12.91 Billion USD | -7.29% |
| 2021 Q1 | 13.19 Billion USD | -5.32% |
| 2021 Q4 | 12.91 Billion USD | -0.06% |
| 2021 Q3 | 12.92 Billion USD | -2.49% |
| 2021 Q2 | 13.25 Billion USD | 0.49% |
| 2020 Q2 | 14.22 Billion USD | 4.71% |
| 2020 Q4 | 13.93 Billion USD | -1.81% |
| 2020 Q3 | 14.18 Billion USD | -0.23% |
| 2020 FY | 13.93 Billion USD | 0.27% |
| 2020 Q1 | 13.58 Billion USD | -2.25% |
| 2019 Q4 | 13.89 Billion USD | 2.99% |
| 2019 Q3 | 13.49 Billion USD | 1.15% |
| 2019 Q1 | 12.62 Billion USD | 2.99% |
| 2019 Q2 | 13.33 Billion USD | 5.67% |
| 2019 FY | 13.89 Billion USD | 13.36% |
| 2018 FY | 12.25 Billion USD | 10.88% |
| 2018 Q2 | 11.69 Billion USD | -2.93% |
| 2018 Q3 | 11.73 Billion USD | 0.28% |
| 2018 Q4 | 12.25 Billion USD | 4.47% |
| 2018 Q1 | 12.05 Billion USD | 9.03% |
| 2017 Q4 | 11.05 Billion USD | 8.12% |
| 2017 Q2 | 10.18 Billion USD | 4.7% |
| 2017 Q1 | 9.72 Billion USD | -9.49% |
| 2017 FY | 11.05 Billion USD | 2.85% |
| 2017 Q3 | 10.22 Billion USD | 0.38% |
| 2016 Q1 | 10.34 Billion USD | 2.14% |
| 2016 Q2 | 10.11 Billion USD | -2.28% |
| 2016 Q3 | 9.99 Billion USD | -1.2% |
| 2016 FY | 10.74 Billion USD | 6.1% |
| 2016 Q4 | 10.74 Billion USD | 7.59% |
| 2015 Q2 | 4.18 Billion USD | 17.92% |
| 2015 Q3 | 10.16 Billion USD | 142.74% |
| 2015 Q1 | 3.54 Billion USD | 1.36% |
| 2015 Q4 | 10.12 Billion USD | -0.31% |
| 2015 FY | 10.12 Billion USD | 189.22% |
| 2014 Q2 | 3.35 Billion USD | 8.54% |
| 2014 Q3 | 3.27 Billion USD | -2.37% |
| 2014 Q1 | 3.08 Billion USD | -4.73% |
| 2014 FY | 3.5 Billion USD | 8.02% |
| 2014 Q4 | 3.5 Billion USD | 7.0% |
| 2013 Q3 | 3.12 Billion USD | 6.3% |
| 2013 FY | 3.24 Billion USD | 2.41% |
| 2013 Q4 | 3.24 Billion USD | 3.77% |
| 2013 Q2 | 2.93 Billion USD | 4.05% |
| 2013 Q1 | 2.82 Billion USD | -10.78% |
| 2012 Q4 | 3.16 Billion USD | 6.66% |
| 2012 FY | 3.16 Billion USD | 20.73% |
| 2012 Q1 | 2.8 Billion USD | 6.95% |
| 2012 Q2 | 2.89 Billion USD | 3.09% |
| 2012 Q3 | 2.96 Billion USD | 2.66% |
| 2011 Q1 | 2.61 Billion USD | -0.9% |
| 2011 Q3 | 2.56 Billion USD | 0.11% |
| 2011 FY | 2.62 Billion USD | -0.77% |
| 2011 Q4 | 2.62 Billion USD | 2.1% |
| 2011 Q2 | 2.56 Billion USD | -2.04% |
| 2010 Q1 | 2.26 Billion USD | -1.01% |
| 2010 FY | 2.64 Billion USD | 15.42% |
| 2010 Q4 | 2.64 Billion USD | 13.73% |
| 2010 Q3 | 2.32 Billion USD | 1.44% |
| 2010 Q2 | 2.29 Billion USD | 1.06% |
| 2009 Q3 | 2.42 Billion USD | -4.06% |
| 2009 Q4 | 2.28 Billion USD | -5.71% |
| 2009 FY | 2.28 Billion USD | -14.33% |
| 2009 Q1 | 2.55 Billion USD | -4.41% |
| 2009 Q2 | 2.53 Billion USD | -0.92% |
| 2008 Q1 | 2.63 Billion USD | -14.75% |
| 2008 Q4 | 2.67 Billion USD | -3.39% |
| 2008 Q3 | 2.76 Billion USD | 4.41% |
| 2008 FY | 2.67 Billion USD | -13.62% |
| 2008 Q2 | 2.64 Billion USD | 0.45% |
| 2007 FY | 3.09 Billion USD | 120.56% |
| 2007 Q1 | 1.36 Billion USD | -2.89% |
| 2007 Q2 | 4.29 Billion USD | 215.54% |
| 2007 Q3 | 2.82 Billion USD | -34.32% |
| 2007 Q4 | 3.09 Billion USD | 9.59% |
| 2006 Q1 | 1.38 Billion USD | -5.45% |
| 2006 Q2 | 1.33 Billion USD | -3.61% |
| 2006 Q3 | 1.29 Billion USD | -3.0% |
| 2006 FY | 1.4 Billion USD | -3.97% |
| 2006 Q4 | 1.4 Billion USD | 8.62% |
| 2005 Q4 | 1.46 Billion USD | -3.67% |
| 2005 Q1 | 2.28 Billion USD | -2.46% |
| 2005 Q2 | 1.52 Billion USD | -33.28% |
| 2005 Q3 | 1.51 Billion USD | -0.36% |
| 2005 FY | 1.46 Billion USD | -37.54% |
| 2004 FY | 2.33 Billion USD | -4.54% |
| 2004 Q3 | 2.31 Billion USD | 0.75% |
| 2004 Q1 | 2.31 Billion USD | -5.57% |
| 2004 Q2 | 2.29 Billion USD | -0.91% |
| 2004 Q4 | 2.33 Billion USD | 1.26% |
| 2003 Q3 | 373.32 Million USD | 13.75% |
| 2003 Q2 | 328.2 Million USD | -8.12% |
| 2003 FY | 2.45 Billion USD | 495.44% |
| 2003 Q4 | 2.45 Billion USD | 556.44% |
| 2003 Q1 | 357.21 Million USD | -13.21% |
| 2002 FY | 411.56 Million USD | 10.57% |
| 2002 Q3 | 341.85 Million USD | -5.89% |
| 2002 Q2 | 363.24 Million USD | 3.67% |
| 2002 Q1 | 350.38 Million USD | -5.87% |
| 2002 Q4 | 411.56 Million USD | 20.39% |
| 2001 Q3 | 352.11 Million USD | 5.69% |
| 2001 Q2 | 333.15 Million USD | 2.44% |
| 2001 Q1 | 325.22 Million USD | -0.07% |
| 2001 FY | 372.21 Million USD | 14.37% |
| 2001 Q4 | 372.21 Million USD | 5.71% |
| 2000 Q4 | 325.45 Million USD | -4.8% |
| 2000 FY | 325.45 Million USD | 9.05% |
| 2000 Q1 | 271.82 Million USD | -8.92% |
| 2000 Q3 | 341.85 Million USD | 7.48% |
| 2000 Q2 | 318.06 Million USD | 17.01% |
| 1999 FY | 298.44 Million USD | 44.8% |
| 1999 Q3 | 197.5 Million USD | 4.77% |
| 1999 Q4 | 298.44 Million USD | 51.11% |
| 1999 Q2 | 188.5 Million USD | 3.91% |
| 1999 Q1 | 181.4 Million USD | -11.99% |
| 1998 Q1 | 248.7 Million USD | -10.39% |
| 1998 Q4 | 206.1 Million USD | -6.23% |
| 1998 Q3 | 219.8 Million USD | 2.66% |
| 1998 Q2 | 214.1 Million USD | -13.91% |
| 1998 FY | 206.1 Million USD | -25.74% |
| 1997 Q3 | 159.4 Million USD | 9.18% |
| 1997 Q1 | 148.4 Million USD | -1.2% |
| 1997 Q2 | 146 Million USD | -1.62% |
| 1997 Q4 | 277.53 Million USD | 74.11% |
| 1997 FY | 277.53 Million USD | 84.77% |
| 1996 Q4 | 150.2 Million USD | 18.92% |
| 1996 Q1 | 90.7 Million USD | 5.19% |
| 1996 Q2 | 115.5 Million USD | 27.34% |
| 1996 Q3 | 126.3 Million USD | 9.35% |
| 1996 FY | 150.2 Million USD | 74.21% |
| 1995 Q4 | 86.22 Million USD | 19.75% |
| 1995 Q3 | 72 Million USD | 16.13% |
| 1995 Q2 | 62 Million USD | -2.67% |
| 1995 FY | 86.22 Million USD | 79.9% |
| 1995 Q1 | 63.7 Million USD | 32.91% |
| 1994 Q4 | 47.92 Million USD | -18.21% |
| 1994 Q1 | 29.5 Million USD | -7.23% |
| 1994 Q2 | 32.8 Million USD | 11.19% |
| 1994 Q3 | 58.6 Million USD | 78.66% |
| 1994 FY | 47.92 Million USD | 50.72% |
| 1993 Q1 | 22.5 Million USD | -14.12% |
| 1993 Q2 | 36 Million USD | 60.0% |
| 1993 Q4 | 31.8 Million USD | 4.61% |
| 1993 Q3 | 30.4 Million USD | -15.56% |
| 1993 FY | 31.8 Million USD | 21.37% |
| 1992 Q4 | 26.2 Million USD | 25.36% |
| 1992 FY | 26.2 Million USD | 85.82% |
| 1992 Q2 | 13.8 Million USD | 20.0% |
| 1992 Q3 | 20.9 Million USD | 51.45% |
| 1992 Q1 | 11.5 Million USD | -18.44% |
| 1991 Q3 | 13 Million USD | 9.24% |
| 1991 FY | 14.1 Million USD | 10.16% |
| 1991 Q2 | 11.9 Million USD | 15.53% |
| 1991 Q4 | 14.1 Million USD | 8.46% |
| 1991 Q1 | 10.3 Million USD | -19.53% |
| 1990 Q4 | 12.8 Million USD | 45.45% |
| 1990 FY | 12.8 Million USD | 113.33% |
| 1990 Q2 | 7 Million USD | 20.69% |
| 1990 Q1 | 5.8 Million USD | -3.33% |
| 1990 Q3 | 8.8 Million USD | 25.71% |
| 1989 Q4 | 6 Million USD | -7.69% |
| 1989 Q3 | 6.5 Million USD | 0.0% |
| 1989 FY | 6 Million USD | -53.49% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -1830.294% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -9452.336% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -1850.022% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -4449.984% |
| bluebird bio, Inc. | 424.62 Million USD | -2736.721% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -17418.289% |
| Imunon, Inc. | 8.53 Million USD | -141105.124% |
| Editas Medicine, Inc. | 150.05 Million USD | -7927.27% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 41.439% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -243.615% |
| Myriad Genetics, Inc. | 312.9 Million USD | -3749.601% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -1081.617% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -2371.049% |
| Verastem, Inc. | 71.18 Million USD | -16821.262% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 82.507% |
| Waters Corporation | 3.47 Billion USD | -246.479% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 76.784% |
| Nektar Therapeutics | 267.04 Million USD | -4410.609% |
| Perrigo Company plc | 6.04 Billion USD | -99.388% |
| Dynavax Technologies Corporation | 375.02 Million USD | -3111.901% |
| Illumina, Inc. | 4.36 Billion USD | -175.891% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -34142.149% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -6053.838% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -4596.447% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -32200.225% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -537.305% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -14512.352% |
| Evolus, Inc. | 209.68 Million USD | -5644.467% |
| Adicet Bio, Inc. | 37.12 Million USD | -32349.892% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -29844.315% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | -69.484% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -1722.879% |
| FibroGen, Inc. | 585.72 Million USD | -1956.484% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -144.925% |
| OPKO Health, Inc. | 622.47 Million USD | -1835.069% |
| Homology Medicines, Inc. | 118.53 Million USD | -10062.065% |
| Geron Corporation | 146.12 Million USD | -8143.104% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -197.379% |
| Exelixis, Inc. | 678.44 Million USD | -1675.442% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -59913.95% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -96001.803% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -4702.638% |
| Zoetis Inc. | 9.29 Billion USD | -29.59% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -2932.128% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -24394.469% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -133.9% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -24764.073% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -362.682% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -400.798% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -10391.412% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -630.262% |
| Blueprint Medicines Corporation | 918.64 Million USD | -1211.22% |
| Insmed Incorporated | 1.66 Billion USD | -624.858% |
| TG Therapeutics, Inc. | 169.08 Million USD | -7023.873% |
| Incyte Corporation | 1.59 Billion USD | -656.492% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -915.975% |